Evidence map›Paper›PMID 39940365›Full record

ArticleNutrients2025

Effect of Moderately High-Dose Vitamin D3 Supplementation on Mortality in Patients Hospitalized for COVID-19 Infection.

Liza Dalma Sümegi, Marina Varga, Veronika Kadocsa, Balázs Szili, Márk Stempler, Péter András Lakatos, Zsuzsanna Németh, István Takács

Abstract read
In one paragraph

Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Liza Dalma SümegiDepartment of Internal Medicine and Oncology, Semmelweis University, Korányi S. U 2/a, 1083 Budapest, Hungary.
Marina VargaDepartment of Laboratory Medicine, Semmelweis University, Nagyvárad Tér 4, 1089 Budapest, Hungary.ORCID 0000-0002-6192-8940
Veronika KadocsaDepartment of Pulmonology, Semmelweis University, Tömő U. 25-29, 1083 Budapest, Hungary.
Balázs SziliDepartment of Internal Medicine and Oncology, Semmelweis University, Korányi S. U 2/a, 1083 Budapest, Hungary.ORCID 0000-0002-2816-9487
Márk StemplerDepartment of Internal Medicine and Oncology, Semmelweis University, Korányi S. U 2/a, 1083 Budapest, Hungary.ORCID 0009-0005-3268-7446
Péter András LakatosDepartment of Internal Medicine and Oncology, Semmelweis University, Korányi S. U 2/a, 1083 Budapest, Hungary.
Zsuzsanna NémethDepartment of Internal Medicine and Oncology, Semmelweis University, Korányi S. U 2/a, 1083 Budapest, Hungary.ORCID 0000-0003-2586-6639
István TakácsDepartment of Internal Medicine and Oncology, Semmelweis University, Korányi S. U 2/a, 1083 Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite a large number of published studies, the effect of vitamin D3 supplementation on mortality in hospitalized patients, as well as the recommended dose and duration of therapy, is unclear. In our retrospective study, we aimed to investigate the impact of vitamin D deficiency and moderately high-dose vitamin D3 supplementation on mortality and disease outcomes in patients with COVID-19 infection.

methodsWe analyzed data from 148 COVID-19-infected hospitalized patients in two different departments, Internal Medicine and Oncology, at Semmelweis University. The severity of COVID-19 and the treatment used were the same except at one of the departments, where patients received circa 90,000 IU of vitamin D3. We compared in-hospital mortality rates between the groups. In a subgroup analysis, we evaluated the efficacy and safety of vitamin D3 supplementation by assessing 25(OH)D and 1,25(OH)

resultsAs a result of the supplementation, the deficiency was resolved in 4 days in deficient patients, and none of the 25(OH)D or 1,25(OH)

conclusionsThe supplemental dosage, 3 × 30,000 IU of vitamin D3, is effective and safe and may reduce mortality in COVID-19 infection.

Indexed as

CholecalciferolCOVID-19COVID-19 Drug TreatmentDietary SupplementsVitamin D DeficiencyVitaminsAgedAged, 80 and overFemaleHospitalizationHospital MortalityHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2CholecalciferolVitamin DVitaminsCOVID-19moderately high-dose supplementationmortalityvitamin D

Identifiers

PMID39940365
PMCPMC11820488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.